Rutgers Business SchoolPharmaceutical Management Club

Eisai Inc.

Prep Session, March 1, 2007Elena Arvanitis

Site visit, March 2, 2007

Seminar topicInvesting in the Rx Industry – Mixing Medicine with Business

HISTORY

PMSIG Prep session 03/01/07

• Eisai Co Ltd founded in Japan in 1941 as Nihon Eisai Co Ltd• Eisai USA established in 1981• Eisai Inc established in 1995 as US prescription pharmaceutical sales company

Research: Eisai Research Institute of Boston, Andover, MADiscovery Research (1987)Process Research and Bulk Production of pharmaceuticals for clinical trials (1994)

Eisai Inc, Research Triangle Park NC Pharmaceutical Production and Formulation R&D facility (1997)

Eisai Medical Research, Ridgefield, NJ Clinical Research and Clinical Drug Development (2002)

Rutgers Business SchoolPharmaceutical Management Club

QUICK FACTS

PMSIG Prep session 03/01/07Rutgers Business School

Pharmaceutical Management Club

• More than 9,000 employees worldwide

• Eisai Inc had $2.2 billion in sales for 2005(fiscal year ending March 31, 2006)

• During the period of 1998 to 2005, Eisai Inc. moved up in the rankings of U.S. pharmaceutical companies from 44 to 19 (based on revenues).

• Eisai Co shares are traded on the Tokyo Stock Exchange and the Osaka Securities Exchange. American Depository Receipts (ESALY.PK) are available through JPMorgan Chase

Last trade: $50.65 52-week: $41.15 - $55.55

PRODUCTS

PMSIG Prep session 03/01/07

ARICEPT® (donepezil hydrochloride) tabletsDiscovered and developed by EisaiApproved by the FDA in 1996Treatment of mild to moderate Alzeimer’s disease symptoms.

ACIPHEX® (rabeprazole sodium) tabletsDiscovered and developed by EisaiApproved by the FDA in 1999Treatment of acid reflux (proton pump inhibitor)In combination with appropriate antibiotics, approved by the FDA for the eradication of H. Pylori infections, responsible for peptic ulcers.

NeurologyGastrointestinal DisordersOncology / Critical Care

Rutgers Business SchoolPharmaceutical Management Club

PRODUCTS

PMSIG Prep session 03/01/07

CEREBYX® (phosphenytoin sodium) injectableAcquired exclusive US rights from PfizerApproved by the FDA in 1996Used to control general epileptic convulsions and to prevent seizures during brain surgery

ZONEGRAN® (zonisamide) capsulesAcquired from Elan in April 2004Approved by the FDA in 2000Treatment of epileptic symptoms

FRAGMIN® (dalteparin sodium) injectableAcquired exclusive US rights from PfizerClot preventing agent for the prevention of deep vein thrombosis which may lead to pulmonary embolism

®®

NeurologyGastrointestinal DisordersOncology / Critical Care

Rutgers Business SchoolPharmaceutical Management Club

ALLIANCES

PMSIG Prep session 03/01/07

From the start, Eisai pioneered strategic co-promotions or product-focused collaborations to achieve its goal of becoming an integrated pharmaceutical business (R&D, manufacturing, marketing, distribution).

Pfizer Aricept (co-promotion), Cerebyx (exclusive U.S. rights), Fragmin (exclusive U.S. rights)

Ortho-McNeil Aciphex (co-promotion)

Elan Zonegran (acquisition)

Teva Pharma. Razagiline (co-promotion, co-development)

Novartis Rufinamide (acquisition)

Eisai Inc.Investing in the Pharmaceutical Industry …

Mixing Medicine with BusinessMarch 2, 2007

8:00 am – 8:45 am Breakfast / ”Meet and Greet” with EisaiManagement

8:45 am – 9:00 am Introduction / Kickoff Mr. Gregory AltamuraHuman Resources Director, Corporate ER & Recruitment

9:00 am – 9:45 am Financial Stakeholder Perspectives Mr. Robert Feeney,Director, Investor & Government Relations

9:45 am – 10:30 am Building a Brand Ms. Kim Trapani,Associate Director, Zonegran

10:30 am – 10:45 am Break

10:45 am – 11:30 am Global Medical & Marketing Services Mr. Andrew GreeneImpacting the Product Portfolio Director of Marketing, New

Products

11:30 am – 12:00 pm Our Value Proposition to all Mr. Frank CirielloStakeholders VP, Sales & Marketing

12:00 pm – 12:30 pm Q&A / Closing All Presenters

12:30 pm – 1:30 pm Lunch / Networking with EisaiManagement